Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
about
Secukinumab for rheumatology: development and its potential place in therapyComparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesBiologic agents in juvenile spondyloarthropathiesType I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesOld and new treatment targets in axial spondyloarthritisNew treatment targets for axial spondyloarthritisAdvances in managing ankylosing spondylitisCalprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritisSarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.All-Trans Retinoic Acid Improves the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on the Treatment of Ankylosing Spondylitis: An In Vitro StudyJuvenile spondyloarthritis.Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.Evaluation and Treatment of Childhood Enthesitis-Related Arthritis.Two Subsets of Large Vessel Vasculitis Characterized by the Absence or Presence of Spondyloarthritis or its Associated Diseases.Anti-IL17A in Axial Spondyloarthritis-Where Are We At?Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA).Investigational drugs for treating psoriatic arthritis.Biological therapies for spondyloarthritis.Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis.IL-6 biology: implications for clinical targeting in rheumatic disease.IL-17RA in intestinal inflammation: structure, signaling, function, and clinical application.IL-6 blockade in chronic inflammatory diseases.Anti-TNFs in axial spondyloarthritis.Emerging drugs for the treatment of axial and peripheral spondyloarthritis.Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.Advances in use of immunomodulatory agents--a rheumatology perspective.Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).Biologics in spondyloarthritis: TNFα inhibitors and other agents.Pharmacological therapy of spondyloarthritis.Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.An overview of investigational new drugs for treating ankylosing spondylitis.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.Pathogenesis of ankylosing spondylitis - recent advances and future directions.Tocilizumab for treating juvenile idiopathic arthritis.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.Secukinumab (AIN457) in the treatment of ankylosing spondylitis.The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.
P2860
Q26738523-3379663F-C9B1-4180-AE89-475ADBC0CA69Q26764820-0285D8E7-4EC7-48B1-9B9D-992CAFB51CAAQ26764867-73281918-F8FD-4067-BFA6-D538D6447B01Q26766263-D2B858B6-8297-41DE-9EB1-2EEAC9B1E6B8Q26775111-813A614D-DA7A-4111-8316-5AF979391200Q26777084-CDC9FEF5-8DDF-452F-AE17-8AC33577DFC7Q26777906-A10D391D-BE5A-443A-931C-CABB1602232AQ28073999-CE54125A-BB66-499F-98BB-1950540A39D7Q34201927-B49EC72B-DB9E-4A91-B498-E41486B4DFA0Q34941693-33167AFC-1709-40EB-A1E1-56470344E49FQ35605461-45A93BD8-D567-4BCB-BDF5-DD1AB818F3DAQ35614331-CFDAE8F4-C04D-49C8-BDD3-668E937AD278Q35739571-6BB782BD-9B6B-41D1-805F-4D97236AC379Q35800954-FFDA4135-9EA5-44A9-8D8F-AD1E7ACD884FQ35963238-C3C39A36-75EB-4D55-921F-692E5C578E1EQ36498631-0704A464-C747-47DC-9E69-F7D59212839AQ37548004-8470274D-4CDA-45F2-8115-02432AD7E639Q37590576-039F38F3-EE8E-498D-993A-F67672FC5AC2Q38199786-36E043B4-D8E4-4C15-B788-207DE8DB2417Q38206551-6B620045-F439-414A-AA70-6B28229F02F8Q38217223-C70CE438-C1D0-46F5-B0B3-9D844C87E2D9Q38240821-09C3AE0A-CF8E-4D71-BEF3-4E896B90A470Q38241232-2C305A3A-DABF-4DDD-9CA0-77C618AEA01EQ38255855-B3CFA7C2-14C5-4224-90EC-954D6C5D5C34Q38261783-4871DF80-100C-4AC7-AC9B-C0902487484DQ38311916-933EC65D-0DEB-40E5-9E3C-6057B4EB07CAQ38313266-B23583E3-AA5D-43BE-A11A-73BBCE19BBEEQ38411334-9B076505-B19F-4916-93DC-C228F9F01C96Q38431512-08E5AF37-15B7-4EF3-83F0-08F553B43FC7Q38438153-9A7E766E-6A0F-4F86-83F9-8D481310D054Q38522331-0CDB8916-9CE8-4807-A389-D2D405D20BA7Q38527552-87725D52-A422-4725-B8CE-CEA127AD0916Q38611064-8B9CEFF8-2E27-471D-8563-43CE4265311FQ38631462-04B7116E-3DD6-4951-B003-382AE3148AF2Q38687571-606C98DC-F3B5-43A8-8004-A3ACB20C4443Q38690443-9E1C1B49-8ECE-4D60-8295-E3567C46A83DQ38723988-B3F05701-F715-4C6F-BD2B-65029AC40DCAQ38766379-29BB47E3-98DE-457B-B576-FB908038C2F1Q38777116-EF096DE6-FA11-4C99-81EF-569200926635Q38815070-B66F8532-F416-4F60-B944-D486F6B7DAA2
P2860
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Assessment of short-term sympt ...... sed, placebo-controlled trials
@en
Assessment of short-term sympt ...... ed, placebo-controlled trials.
@nl
type
label
Assessment of short-term sympt ...... sed, placebo-controlled trials
@en
Assessment of short-term sympt ...... ed, placebo-controlled trials.
@nl
prefLabel
Assessment of short-term sympt ...... sed, placebo-controlled trials
@en
Assessment of short-term sympt ...... ed, placebo-controlled trials.
@nl
P2093
P2860
P1476
Assessment of short-term sympt ...... sed, placebo-controlled trials
@en
P2093
Benjamin Porter-Brown
Joachim Sieper
Liz Thompson
Olivier Harari
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-203559
P407
P577
2013-06-13T00:00:00Z